Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA

October 5, 2026 7:00 AM

Stoke Therapeutics (Nasdaq: STOK) announced it has completed a meeting with the U.S. Food and Drug Administration to align on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found